# Zavzpret ® (zavegepant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zavegepant

> The FDA approved Zavzpret ® (zavegepant), sponsored by PFIZER INC (PFE), on March 9, 2023 for to treat migraineDrug Trails Snapshot.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Zavzpret ® (zavegepant) FDA approved?

Yes. The FDA approved Zavzpret ® (zavegepant), sponsored by PFIZER INC (PFE), on March 9, 2023 for to treat migraineDrug Trails Snapshot. FDA novel drug approvals: "Zavzpret | zavegepant | 3/9/2023 | To treat migraineDrug Trails Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/zavegepant)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/zavegepant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Zavzpret ® (zavegepant) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | To treat migraineDrug Trails Snapshot, [Migraine](https://sec-api.dev/indications/migraine) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 9, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat migraineDrug Trails Snapshot.
- First seen 2025-02-12, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Zavzpret | zavegepant | 3/9/2023 | To treat migraineDrug Trails Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216386 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230309, review_priority STANDARD; sponsor_name PFIZER; product ZAVZPRET (ZAVEGEPANT HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216386%22
- SEC Form 10-K (accession 0001802768-25-000010): "In March 2023, the FDA approved Zavzpret, the intranasal formulation of zavegepant, and we received a $475 million milestone payment which resulted in partial settlement of the derivative instruments." https://www.sec.gov/Archives/edgar/data/1802768/000180276825000010/rprx-20241231.htm

### May 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." https://clinicaltrials.gov/study/NCT05989048

### May 22, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." https://clinicaltrials.gov/study/NCT05989048?tab=results

## Same indication

- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant) (ABBV)
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan) (LLY)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant) (PFE)
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zavegepant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zavzpret ® (zavegepant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zavegepant

```bibtex
@misc{secapidev_pdufa_zavegepant_20261116,
  title        = {Zavzpret ® (zavegepant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zavegepant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zavegepant_20261116","title":"Zavzpret ® (zavegepant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zavegepant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
